FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

@article{Weisberg2009FLT3IA,
  title={FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.},
  author={Ellen Weisberg and Rosemary Barrett and Qingsong Liu and Richard C. Stone and Nathanael Gray and James D Griffin},
  journal={Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy},
  year={2009},
  volume={12 3},
  pages={81-9}
}
An appealing therapeutic target in AML is constitutively activated, mutant FLT3, which is expressed in a subpopulation of AML patients and is generally a poor prognostic indicator in patients under the age of 65. There are currently several FLT3 inhibitors that are undergoing clinical investigation. However, the discovery of drug-resistant leukemic blast cells in FLT3 inhibitor-treated AML patients has prompted the search for novel, structurally diverse FLT3 inhibitors that could be… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 60 extracted citations

Similar Papers

Loading similar papers…